Simulations Plus Inc. (SLP) Upgraded to “Hold” at Zacks Investment Research
According to Zacks, “Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. They have two other businesses, Words+, Inc. and FutureLab, which are based on its proprietary software technologies. “
Simulations Plus (NASDAQ:SLP) traded down 1.39% during trading on Wednesday, hitting $8.52. The stock had a trading volume of 9,365 shares. Simulations Plus has a 12 month low of $6.74 and a 12 month high of $11.89. The company has a market cap of $145.27 million, a PE ratio of 31.56 and a beta of -0.26. The company’s 50 day moving average is $8.63 and its 200-day moving average is $8.23.
Simulations Plus (NASDAQ:SLP) last posted its earnings results on Thursday, July 14th. The company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.12 by $0.01. The company had revenue of $6.01 million for the quarter. Simulations Plus had a return on equity of 22.89% and a net margin of 23.58%. On average, equities research analysts predict that Simulations Plus will post $0.28 earnings per share for the current year.
A number of hedge funds have recently modified their holdings of the stock. Menta Capital LLC acquired a new stake in shares of Simulations Plus during the second quarter valued at approximately $105,000. Alambic Investment Management L.P. acquired a new stake in shares of Simulations Plus during the second quarter valued at approximately $146,000. Redmond Asset Management LLC acquired a new stake in shares of Simulations Plus during the second quarter valued at approximately $210,000. BlackRock Fund Advisors raised its stake in shares of Simulations Plus by 16.8% in the second quarter. BlackRock Fund Advisors now owns 35,736 shares of the company’s stock valued at $270,000 after buying an additional 5,145 shares during the last quarter. Finally, Acadian Asset Management LLC raised its stake in shares of Simulations Plus by 291.5% in the first quarter. Acadian Asset Management LLC now owns 45,622 shares of the company’s stock valued at $405,000 after buying an additional 33,970 shares during the last quarter. 25.30% of the stock is currently owned by institutional investors.
Simulations Plus Company Profile
Simulations Plus, Inc (Simulations Plus) develops and produces software for use in pharmaceutical research and for education, and provides consulting and contract research services to the pharmaceutical industry. The Company offers five software products for pharmaceutical research. ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) Predictor is a computer program that takes molecular structures as inputs and predicts over 140 different properties for them at the rate of about 200,000 compounds per hour.
Receive News & Stock Ratings for Simulations Plus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus Inc. and related stocks with our FREE daily email newsletter.